Drug Type Radiolabeled antibody, Diagnostic radiopharmaceuticals |
Synonyms 111-indium labelled h 11B6 + [1] |
Target |
Mechanism KLK2 inhibitors(Kallikrein 2 inhibitors), Ionising radiation emitters, Radionuclide imaging enhancers + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 2 | US | 18 Sep 2019 | |
Neoplasm Metastasis | Phase 2 | US | 18 Sep 2019 | |
Prostatic Cancer | Preclinical | - | - | |
Prostatic Cancer | Preclinical | - | - | |
Prostatic Cancer | Preclinical | - | - |